FDA OKs J&J’s Tremfya for psoriatic arthritis

The FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies’ Tremfya (guselkumab) for adult patients with active psoriatic arthritis, the first IL-23 inhibitor to receive the nod in the U.S. for these patients.

The FDA first approved Tremfya in July 2017 for adults with plaque psoriasis.

https://seekingalpha.com/news/3590962-fda-oks-j-and-js-tremfya-for-psoriatic-arthritis